Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Aprea Therapeutics Inc (NASDAQ: APRE) was $1.8 for the day, up 10.09% from the previous closing price of $1.63. In other words, the price has increased by $10.09 from its previous closing price. On the day, 0.49 million shares were traded.
Ratios:
Our analysis of APRE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On December 16, 2020, Berenberg started tracking the stock assigning a Buy rating and target price of $37.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 03 ’25 when Gilad Oren bought 5,500 shares for $1.84 per share. The transaction valued at 10,110 led to the insider holds 345,620 shares of the business.
Duey Marc sold 6,462 shares of APRE for $29,583 on Oct 18 ’24. The Director now owns 233,651 shares after completing the transaction at $4.58 per share. On Oct 23 ’24, another insider, Gilad Oren, who serves as the President/CEO of the company, bought 500 shares for $3.92 each. As a result, the insider paid 1,958 and bolstered with 333,395 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.78 while its Price-to-Book (P/B) ratio in mrq is 0.64.
Stock Price History:
Over the past 52 weeks, APRE has reached a high of $5.01, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is 5.44%, while the 200-Day Moving Average is calculated to be -35.07%.
Shares Statistics:
A total of 5.51M shares are outstanding, with a floating share count of 4.82M. Insiders hold about 12.88% of the company’s shares, while institutions hold 35.25% stake in the company.
